文献速递高血压

美国成人隐匿性睡眠高血压的估计患病率

Estimated Prevalence of Masked Asleep Hypertension in US Adults.
PubMed 文献 · JAMA Cardiol · 2021-01-01

结果显示,按JNC7标准美国成人隐匿性睡眠高血压患病率为18.8%(95%CI 16.7%-20.8%;

要点

  • 按2017 ACC-AHA标准,美国成人隐匿性睡眠高血压患病率约22.7%。
  • 老年、男性、非西班牙裔黑人、服用降压药者及合并症患者患病率更高。
  • 孤立性隐匿性睡眠高血压(无高日间血压)按JNC7标准约占11.9%。

核心结论

  • 美国成人隐匿性睡眠高血压患病率高,按JNC7标准为18.8%,按2017 ACC-AHA标准为22.7%。

研究设计与样本

  • 数据收集于2000-2016年,分析于2019年3月4日至2020年6月29日。

主要发现

  • 按2017 ACC-AHA标准,患病率在≥65岁人群为24.4%(95%CI 20.7%-28.0%),男性为27.0%(95%CI 24.1%-29.9%),非西班牙裔黑人为28.7%(95%CI 25.4%-32.0%),服用降压药者为24.4%(95%CI 21.1%-27.8%),有日间隐匿性高血压者为44.7%(95%CI 40.1%-49.3%),糖尿病患者为27.6%(95%CI 23.5%-31.8%),肥胖者为24.3%(95%CI 21.8%-26.9%),慢性肾脏病者为21.5%(95%CI 17.3%-25.6%)。

关键数值与推荐

  • JNC7标准:高诊室血压定义为诊室收缩压/舒张压≥140/90 mm Hg;高睡眠血压定义为平均睡眠收缩压/舒张压≥120/70 mm Hg。
  • 2017 ACC-AHA标准:高诊室血压定义为诊室收缩压/舒张压≥130/80 mm Hg;高睡眠血压定义为平均睡眠收缩压/舒张压≥110/65 mm Hg。
  • 隐匿性睡眠高血压定义为高睡眠血压且无高诊室血压。

临床怎么用

  • 提示临床应关注诊室血压正常但存在睡眠高血压风险的人群,尤其是老年人、男性、非西班牙裔黑人、服用降压药者及合并糖尿病、肥胖或慢性肾脏病者。
  • 对于上述高风险患者,可考虑使用24小时动态血压监测以识别隐匿性睡眠高血压。

局限性

  • NHANES参与者的隐匿性睡眠高血压状态为插补估计,非直接动态血压监测测量。
  • 研究未提供治疗睡眠高血压对心血管风险降低获益的数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: High blood pressure (BP) during sleep (asleep blood pressure) is associated with an increased risk of cardiovascular disease, but a national prevalence estimate of masked asleep hypertension (high BP while sleeping but without high BP measured in the clinic [clinic BP]) for the United States is lacking. OBJECTIVES: To estimate the prevalence of masked asleep hypertension among US adults by using BP thresholds from the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7) and the 2017 American College of Cardiology-American Heart Association (ACC-AHA) BP guidelines. DESIGN, SETTING, AND PARTICIPANTS: This cohort analysis pooled data from 3000 participants in 4 US population-based studies that conducted 24-hour ambulatory BP monitoring (ABPM) and 17 969 participants in the 2011-2016 National Health and Nutrition Examination Survey (NHANES) without ABPM. Masked asleep hypertension status in NHANES was imputed using a 2-stage multiple imputation process. Data were collected from 2000 to 2016 and analyzed from March 4, 2019, to June 29, 2020. MAIN OUTCOMES AND MEASURES: High clinic BP was defined as clinic systolic BP (SBP)/diastolic BP (DBP) of at least 140/90 mm Hg using JNC7 and at least 130/80 mm Hg using 2017 ACC-AHA guidelines. High asleep BP was defined as mean asleep SBP/DBP of at least 120/70 mm Hg for JNC7 and at least 110/65 mm Hg for the 2017 ACC-AHA guidelines. Masked asleep hypertension was defined as high asleep BP without high clinic BP. RESULTS: For the 3000 pooled cohort participants, the mean (SD) age was 52.0 (12.0) years, and 62.6% were women. For the 17 969 NHANES participants, the mean (SD) age was 46.7 (17.5) years, and 51.8% (weighted) were women. The estimated prevalence of masked asleep hypertension among US adults was 18.8% (95% CI, 16.7%-20.8%; 44.4 million US adults) using the JNC7 guideline and 22.7% (95% CI, 20.6%-24.8%; 53.7 million US adults) using the 2017 ACC-AHA guideline criteria. The prevalence of masked asleep hypertension was higher among older adults (aged ≥65 years, 24.4% [95% CI, 20.7%-28.0%]), men (27.0% [95% CI, 24.1%-29.9%]), non-Hispanic Black individuals (28.7% [95% CI, 25.4%-32.0%]), those who were taking antihypertensives (24.4% [95% CI, 21.1%-27.8%]), those who had masked daytime hypertension (44.7% [95% CI, 40.1%-49.3%]), and those with diabetes (27.6% [95% CI, 23.5%-31.8%]), obesity (24.3% [95% CI, 21.8%-26.9%]), or chronic kidney disease (21.5% [95% CI, 17.3%-25.6%]) using the 2017 ACC-AHA guideline. An estimated 11.9% of US adults (28.2 million) had isolated masked asleep hypertension (masked asleep hypertension but without high awake BP) using JNC7 guideline criteria, as did an estimated 13.3% (31.5 million) using 2017 ACC-AHA guideline criteria. CONCLUSIONS AND RELEVANCE: These findings suggest that the prevalence of masked asleep hypertension is high among US adults. Data are needed on the cardiovascular risk reduction benefits of treating asleep hypertension.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Li S, Schwartz JE, Shimbo D, et al. Estimated Prevalence of Masked Asleep Hypertension in US Adults. JAMA Cardiol. 2021. PMID: 33112362. doi:10.1001/jamacardio.2020.5212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。